Beantown Biotech Awarded Top 10 Preeminent CRO by Life Sciences Review
Life Sciences Review named Beantown Biotech a Top 10 Preeminent CRO in 2023, recognizing the company for its extensive scientific expertise, broad capabilities, and unwavering client-first approach.
In an interview with Life Sciences Review, Beantown Biotech CEO and founder, Jim Breunig, stated, “We are not just another CRO or vendor; our clients view us as their partners. They rely on our knowledge, infrastructure, and specialized approach that goes beyond business transactions to meet their drug discovery requirements.”
“The all-around capabilities of Beantown Biotech make it an ideal partner for biotechnology companies...”
“A trusted drug discovery partner across multiple disciplines, Beantown Biotech's expertise encompasses a diverse array of therapeutic areas...”
“Committed to a strong customer-centric ethos...”